Advances in microenvironment of chronic myelogenous leukemia stem cells and their response to drug therapy
HE Ling1,2 ZHANG Xiaoyan3 YANG Yazhi2 LI Jian2▲
1.Department of Clinical, Jiangxi Health Vocational College, Jiangxi Province, Nanchang 330052, China;
2.Department of Hematology, Graduate School of Medicine, Nanchang University, Jiangxi Province, Nanchang 330006, China;
3.Medical College of Nanchang University, Jiangxi Province, Nanchang 330006, China
Abstract：Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disease. With the use of chemotherapy drugs such as tyrosine kinase, improve its clinical remission rate, but drug resistance is up to 15 percent and rising every year. It was found that residual leukemia stem cells (LSCs) in bone marrow microenvironment (BM) play an important role in the acquisition of drug resistance in patients with chronic myelogenous leukemia. LSCs secrete certain cytokines, which play a role in remodeling BM and establishing protective “niches”. Among them, the cytokine CCL3 in the microenvironment can recruit Nestin+ mesenchymal stem cells (MSCs) to form a protective “niche” to shelter LSCs; then TGF-β1 converts MSCs Nestin+ to -SMA +MSCs, becoming a mature “niche” protecting LSCs. Thereby tolerating the killing of chemotherapy drugs, leading to disease recurrence. On the other hand, the bone marrow microenvironment can cause abnormalities in the signaling pathways of LSCs, epigenetic changes, and increased activity of transmembrane transport proteins through a variety of mechanisms, resulting in the “monitoring” of LSCs to escape the immune system. This article reviews the BM and LSCs mediated chronic myelogenous leukemia drug resistance.
贺玲1,2 张小燕3 杨雅芝2 李剑2▲. 慢性粒细胞白血病干细胞的微环境及对药物治疗反应的研究进展[J]. 中国医药导报, 2019, 16(8): 35-38.
HE Ling1,2 ZHANG Xiaoyan3 YANG Yazhi2 LI Jian2▲. Advances in microenvironment of chronic myelogenous leukemia stem cells and their response to drug therapy. 中国医药导报, 2019, 16(8): 35-38.
[1] Morrison SJ，Scadden DT. The bone marrow niche for hae-matopoietic stem cells [J]. Nature，2014，505（7483）：327-334.
[2] Rosti G，Castagnetti F，Gugliotta G，et al. Tyrosine kinase inhibitors in chronic myeloid leukaemia：Which，when，for whom [J]. Nat Rev Clin Oncol，2017，14（3）：141-154.
[3] Karanu FN，Murdoch B，Gallacher L，et al. The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells [J]. Exp Med，2000，192（9）：1365-1372.
[4] Medyouf H. The microenvironment in human myeloid malignancies：Emerging concepts and therapeutic implications [J]. Blood，2017，129（12）：1617-1626.
[5] Mukaida N，Tanabe Y，Baba T. Chemokines as a conductor of bone marrow microenvironment in chronic myeloid leukemia [J]. Int J Mol Sci，2017，18（8）：830-835.
[6] Christopher MJ，Liu F，Hilton MJ，et al. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization [J]. Blood，2009，114（7）：1331-1339.
[7] Jin L，Tabe Y，Konoplev S，et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia （CML） cell migration to bone marrow stroma and promotes survival of quiescent CML cells [J]. Mol Cancer Ther，2008，7（1）：48-58.
[8] Zhang B，Ho Y，Huang Q，et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia [J]. Cancer Cell，2012，21（4）：577-592.
[9] Mendelson A，Frenette PS. Hematopoietic stem cell niche maintenance during homeostasis and regeneration [J]. Nat Med，2014，20（8）：833-846.
[10] Bhatia R，McGlave PB，Dewald GW，et al. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia：Role of malignant stromal macr-ophages [J]. Blood，1995，85（12）：3636-3645.
[11] Camacho V，McClearn V，Patel S，et al. Regulation of normal and leukemic stem cells through cytokine signaling and the microenvir-onment [J]. Int Hematol，2017，105（5）：566-577.
[12] Vanegas NDP，Vernot JP. Loss of quiescence and self-renewal capacity of hematopoietic stem cell in an in vitro leukemic niche [J]. Exp Hematol Oncol，2017，6（2）：432-435.
[13] Nievergall E，Reynolds J，Kok CH，et al. TGF-alpha and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy [J]. Leukemia，2016，30（6）：1263-1272.
[14] Boyiadzis M，Whiteside TL. The emerging roles of tumor-derived exosomes in hema-tological malignancies [J]. Leu-kemia，2017，31（6）：1259-1268.
[15] Hong CS，Muller L，Whiteside TL，et al. Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia [J]. Immunol，2014，10（5）：160.
[16] Raimondo S，Saieva L，Corrado C，et al. Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism [J]. Cell Commun Signal，2015， 13（8）：175-179.
[17] Duan CW，Shi J，Chen J，et al. Leukemia propagating cells rebuild an evolving in response to therapy [J]. Cancer Cell，2014，25（6）：778-793.
[18] Denizot Y，Fixe P，Liozon E，et al. Serum interleukin-8（IL-8）and IL-6 concentrations in patients with hematologic malignancies [J]. Blood，1996，87（9）：4016-4017.
[19] Taverna S，Amodeo V，Saieva L，et al. Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells [J]. Mol Cancer，2014，11（13）：169.
[20] Corrado C，Saieva L，Raimondo S，et al. Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor [J]. Cell Mol Med，2016，20（10）：1829-1839.
[21] Ng KP，Manjeri A，Lee KL，et al. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition [J]. Blood，2016，123（21）：3316-3326.
[22] Corrado C，Raimondo S，Saieva L，et al. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8- dependent survival of leukemia cells [J]. Cancer Lett，2014，348（1/2）：71-76.
[23] Arrigoni E，Galimberti S，Petrini M，et al. ATP-binding cassette transmembrane transporters and their epigenetic control in cancer [J]. Expert Opin Drug Metab Toxicol，2016，12（12）：1419-1432.
[24] Chen KG，Sikic BI，et al. Molecular pathways：Regulation and therapeutic implications of multidrug resistance [J]. Clin Cancer Res，2012，18（7）：1863-1869.
[25] Taverna V，Di Luca A，Sousa D，et al. Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drugsensitive counterpart cells [J]. Biochim Biophys Acta，2016，1860（3）：618-627.
[26] Taverna L，Bergevoet SM，Gilissen C，et al. Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells [J]. BMC Pharmacol，2010，13（10）：1180-1186.
[27] Raij L，Makers H Gilissen C，et al. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia [J]. Leukemia，2007，21（10）：2094-2102.
[28] Illmer T，Schaich M，Platzbecker U，et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate [J]. Leukemia，2013，18（3）：401-408.
[29] Stromskaya TP，Rybalkina EY，Kruglov SS，et al. Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib [J]. Biochemistry，2011，73（1）：29-37.
[30] Alves R，Fonseca AR，Gonc?觭alves AC，et al. Drug transporters play a key role in the complex process of Imatinib resistance in vitro [J]. Leuk Res，2015，39（3）：355-360.
[31] Hu H，Li Y，Gu J，et al. Antisense oligo-nucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells [J]. Lymphoma，2016，51（4）：694-701.
[32] Gao SM，Xing CY，Chen CQ，et al. miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level [J]. Exp Clin Cancer Res，2016，1（30）：345-350
[33] Irvine DA，Zhang B，Kinstrie R，et al. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 in chronic phase chronic myeloid leukaemia [J]. Sci Rep，2016，9（6）：254-260.
2019, Vol. 16 
京公网安备 11010502046598号